Trials to watch: Four biologics concluding pivotal COPD trials
AbbVie axes midstage Alzheimer's program amid 'evolving landscape'
Sanofi, AbbVie, Roche, Astra earnings
Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal
*please scroll down for all the latest news*